Agios Pharmaceuticals, Inc. (AGIO): A Bull Case Theory [Yahoo! Finance]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Yahoo! Finance
Agios Pharmaceuticals, Inc.'s share was trading at $27.80 as of January 15th. AGIO's trailing and forward P/E were 3.54, respectively according to Yahoo Finance. Photo by Myriam Zilles on Unsplash Agios Pharmaceuticals is a clinical-stage biotech company focused on cellular metabolism through oral, small-molecule allosteric activators of the pyruvate kinase (PK) enzyme. Its lead product, mitapivat, is marketed as PYRUKYND for PK deficiency and received FDA approval in December 2025 under the brand name AQVESME for alpha- and beta-thalassemia. By enhancing PK activity, mitapivat increases ATP levels and reduces 2,3-DPG accumulation in red blood cells, improving cell survival and reducing hemolysis, the main driver of anemia. Phase 3 trials in thalassemia demonstrated strong efficacy, with ENERGIZE showing a 42.3% hemoglobin response in non-transfusion-dependent patients and ENERGIZE-T achieving a 30.4% transfusion reduction in dependent patients. In sickle cell disease, the RISE
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio GrowthGlobeNewswire
- What Catalysts Are Rewriting The Story For Agios Pharmaceuticals (AGIO)? [Yahoo! Finance]Yahoo! Finance
- Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by analysts at JPMorgan Chase & Co. from $20.00 to $25.00. They now have a "neutral" rating on the stock.MarketBeat
- Compass Therapeutics Announces Key Leadership Appointments [Yahoo! Finance]Yahoo! Finance
- Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026GlobeNewswire
AGIO
Earnings
- 10/30/25 - Beat
AGIO
Sec Filings
- 1/12/26 - Form 8-K
- 1/7/26 - Form 4
- 1/5/26 - Form 144
- AGIO's page on the SEC website